28
https://pubmed.ncbi.nlm.nih.gov/38093012
This new study presents an inhaled, single-dose, dry powder aerosol SARS-CoV-2 vaccine that induces strong systemic and mucosal immune responses, providing a promising multivalent platform for fighting COVID-19 and other respiratory infectious diseases.